Bronchiectasis Exacerbation Management

A medical professional explores the management of bronchiectasis exacerbations, detailing the significance of sputum color, the potential for hemoptysis, and the exacerbation of comorbidities such as COPD and asthma.

EP: 1.Overview of Bronchiectasis

EP: 2.Prognosis For Patients Diagnosed With Bronchiectasis

EP: 3.Indicators Leading to Bronchiectasis Testing and Diagnosis

EP: 4.Complications Associated With Bronchiectasis

EP: 5.Current Treatment Options For Bronchiectasis

EP: 6.Respiratory and Physical Therapists Contributing to Comprehensive Bronchiectasis Care

EP: 7.Key Areas of Research and Emerging Therapies In Bronchiectasis Treatment

EP: 8.Diagnosing and Understanding the Pathogenesis of Bronchiectasis

EP: 9.Improving Long-Term Outlook: CT Scans and Underdiagnosis of Bronchiectasis

Now Viewing

EP: 10.Bronchiectasis Exacerbation Management

EP: 11.Social Burden and Goals of Therapy for Patients with Bronchiectasis

EP: 12.Patient Specific Factors: Guiding Treatment in Bronchiectasis

EP: 13.Individualized Therapy for Specific Infections Associated with Bronchiectasis

EP: 14.Other Challenges With Bronchiectasis and Key Takeaways

EP: 15.Identifying Bronchiectasis: Key Clinical Presentations to Consider

EP: 16.Differentiating Bronchiectasis from COPD and Understanding Exacerbations

EP: 17.Long-Term Impact of Bronchiectasis Exacerbations: Disease Progression, Patient Outcomes, and Economic Burden

EP: 18.Managing Bronchiectasis: Treatment Goals, Outcome Measures, and Clinical Decision Resources

EP: 19.Addressing Knowledge Gaps and Treatment Strategies in Bronchiectasis

EP: 20.Challenges and Future Directions in Bronchiectasis Management

Related Videos

Related Content

Advertisement

March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 25th 2025

New Therapies Expanding the MASH Treatment Landscape

Jared Kaltwasser

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle modifications.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 24th 2025

Medicare $2 Drug List Model Could Have Reduced 2021 Out-of-Pocket Generic Costs

Brooke McCormick

The researchers emphasized the need for ongoing research and advocacy to further address drug affordability.

March 23rd 2025

Systemic Immune Response Index Identified as Independent Risk Factor for COPD

Brooke McCormick

The systemic immune response index outperformed other inflammatory markers in predicting chronic obstructive pulmonary disease (COPD).

Related Content

Advertisement

March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 25th 2025

New Therapies Expanding the MASH Treatment Landscape

Jared Kaltwasser

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle modifications.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 24th 2025

Medicare $2 Drug List Model Could Have Reduced 2021 Out-of-Pocket Generic Costs

Brooke McCormick

The researchers emphasized the need for ongoing research and advocacy to further address drug affordability.

March 23rd 2025

Systemic Immune Response Index Identified as Independent Risk Factor for COPD

Brooke McCormick

The systemic immune response index outperformed other inflammatory markers in predicting chronic obstructive pulmonary disease (COPD).